Advertisement

Journal of Gastroenterology

, Volume 48, Issue 5, pp 640–646 | Cite as

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

  • Takeshi Ogura
  • Kenji YamaoEmail author
  • Kazuo Hara
  • Nobumasa Mizuno
  • Susumu Hijioka
  • Hiroshi Imaoka
  • Akira Sawaki
  • Yasumasa Niwa
  • Masahiro Tajika
  • Shinya Kondo
  • Tsutomu Tanaka
  • Yasuhiro Shimizu
  • Vikram Bhatia
  • Kazuhide Higuchi
  • Waki Hosoda
  • Yasushi Yatabe
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Although recent reports indicate that K-ras mutation status is a biomarker that acts as a prognostic factor, only a few analyses of K-ras mutation subtypes have been published. In addition, there are no reports that analyze overall survival and prognostic factors according to K-ras mutation status and subtypes in only unresectable pancreatic cancer (PC) determined from tissues obtained by endoscopic ultrasound-guided fine-needle aspiration.

Methods

We retrospectively analyzed 242 patients who were diagnosed as having unresectable PC with available histological diagnosis. Clinical data collected included sex, age, Eastern Cooperative Oncology Group performance status, carbohydrate antigen (CA) 19-9, primary tumor location, stage (local or metastatic) according to TNM staging, first-line chemotherapy, K-ras mutation status and subtypes (G12D, G12V, and G12R), and overall survival. We analyzed the negative prognostic factors for reduced overall survival in unresectable PC patients using these data.

Results

From multivariate analysis, CA19-9 ≥1000 U/ml (hazard ratio [HR] 1.78, 95 % confidence interval [CI] 1.28–2.46, P < 0.01), metastatic stage (HR 2.26, 95 % CI 1.58–3.24, P < 0.01), and mutant-K-ras (HR 1.76, 95 % CI 1.03–3.01, P = 0.04) were negative prognostic factors, indicating a reduced survival. Among the patients who had K-ras mutation subtypes, CA19-9 ≥1000 U/ml (HR 1.65, 95 % CI 1.12–2.37, P < 0.01), metastatic stage (HR 2.12, 95 % CI 1.44–3.14, P < 0.01), and the presence of the G12D or G12R mutations (HR 1.60, 95 % CI 1.11–2.28) were negative prognostic factors for overall survival.

Conclusions

K-ras mutation status and subtypes may be associated with survival duration in pancreatic cancer patients.

Keywords

K-ras mutation Subtype Pancreatic cancer EUS-FNA 

Notes

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer. 1987;60:2284–303.PubMedCrossRefGoogle Scholar
  2. 2.
    Warshaw AL. Fernandez del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006;107:2589–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148–54.PubMedCrossRefGoogle Scholar
  5. 5.
    Sawaki A, Kanemitsu Y, Mizuno N, Takahashi K, Nakamura T, Ioka T, et al. Practical prognosis index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol. 2008;23:1292–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology. 1991;100:233–8.PubMedGoogle Scholar
  8. 8.
    Kullmann F, Hartmann A, Stohr R, Messmann H, Dollinger MM, Trojan J, et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology. 2011;81:3–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007;109:1561–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36:657–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000;89:469–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Immervoll H, Hoem D, Kuqarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448:788–96.PubMedCrossRefGoogle Scholar
  13. 13.
    Ogura T, Yamao K, Sawaki A, Mizuno M, Hara K, et al. Clinical impact of K-ras mutation analysis in Endoscopic ultrasound-guided fine needle aspiration specimens from pancreatic masses. Gastrointest Endosc. 2012;75:769–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc. 1997;45:387–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamao K, Sawaki A, Mizuno N, Shimizu Y, Yatabe Y, Koshikawa T. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB): past, present, and future. J Gastroenterol. 2005;40:1013–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Yatabe Y, Koqa T, Mitsudomi T, Takahashi T. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol. 2004;203:645–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 2006;8:335–41.PubMedCrossRefGoogle Scholar
  18. 18.
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:1413–7.CrossRefGoogle Scholar
  19. 19.
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.PubMedGoogle Scholar
  20. 20.
    Cox DR. Regression models and life-tables. J R Stat Soc B. 1984;34:588–91.Google Scholar
  21. 21.
    Rozenblum E, Shutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731–4.PubMedGoogle Scholar
  22. 22.
    Hiyama E, Kodama T, Shinbara K, Iwao T, Itho M, Hiyama K, et al. Telomerase activity is deleted in pancreatic cancer but not in benign tumors. Cancer Res. 1997;57:326–31.PubMedGoogle Scholar
  23. 23.
    Koorstra JBM, Hustinx SR, Offerhaus GJA, Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008;8:110–25.PubMedCrossRefGoogle Scholar
  24. 24.
    Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.PubMedCrossRefGoogle Scholar
  25. 25.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
  26. 26.
    Hruban RH, Goggins M, Parsons J, Kem SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969–72.PubMedGoogle Scholar
  27. 27.
    Span M, Moerkerek PT, De Goeij AF, Arends JW. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer. 1996;69:241–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Andreyev NJH, Norman AR, Cunningham D, Oates J, Dix BR, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study. Br J Cancer. 2001;85:692–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Vega J, Iniesta P, Caldes T, Sanchez A, Lopez J, Dejuan C, et al. Association of K-ras codon 12 transversions with short survival in non-small cell lung cancer. Int J Oncol. 1996;9:1307–11.PubMedGoogle Scholar
  30. 30.
    Keohavong P, Demichele MAA, Melacrions AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas-relationship to prognosis. Clin Cancer Res. 1999;2:411–8.Google Scholar
  31. 31.
    John J, Frech M, Wittinghofer A. Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation resection. J Biol Chem. 1998;263:792–9.Google Scholar
  32. 32.
    Krengle U, Schlichting L, Scherer A, Schumann R, Frech M, John J, et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. J Biol Chem. 1989;264:86–92.Google Scholar
  33. 33.
    Al-Mulla F, Mackenzie EM. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol. 2001;195:549–56.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2012

Authors and Affiliations

  • Takeshi Ogura
    • 1
    • 5
  • Kenji Yamao
    • 1
    Email author
  • Kazuo Hara
    • 1
  • Nobumasa Mizuno
    • 1
  • Susumu Hijioka
    • 1
  • Hiroshi Imaoka
    • 1
  • Akira Sawaki
    • 1
  • Yasumasa Niwa
    • 2
  • Masahiro Tajika
    • 2
  • Shinya Kondo
    • 2
  • Tsutomu Tanaka
    • 2
  • Yasuhiro Shimizu
    • 3
  • Vikram Bhatia
    • 4
  • Kazuhide Higuchi
    • 5
  • Waki Hosoda
    • 6
  • Yasushi Yatabe
    • 6
  1. 1.Department of GastroenterologyAichi Cancer Center HospitalNagoyaJapan
  2. 2.Department of EndoscopyAichi Cancer Center HospitalNagoyaJapan
  3. 3.Department of Gastroenterological SurgeryAichi Cancer Center HospitalNagoyaJapan
  4. 4.Department of HepatologyInstitute of Liver and Biliary Sciences (ILBS)DelhiIndia
  5. 5.Second Department of Internal MedicineOsaka Medical CollegeOsakaJapan
  6. 6.Department of Pathology and Molecular DiagnosticsAichi Cancer Center HospitalNagoyaJapan

Personalised recommendations